CNS & Neurological Disorders - Drug Targets
Title:Commentary: Toward a Personalized Medicine in Wake-Up Stroke?
Volume: 16 Issue: 10
Author(s): Burak Yulug*, Lutfu Hanoglu and Ertugrul Kilic
Affiliation:
- Regenerative and Restorative Medical Research Center (REMER), University of Istanbul-Medipol, Istanbul,Turkey
Export Options
About this article
Cite this article as:
Yulug Burak*, Hanoglu Lutfu and Kilic Ertugrul , Commentary: Toward a Personalized Medicine in Wake-Up Stroke?, CNS & Neurological Disorders - Drug Targets 2017; 16 (10) . https://dx.doi.org/10.2174/1871527316666170727124327
DOI https://dx.doi.org/10.2174/1871527316666170727124327 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
43
2
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Role of Resveratrol in Modulating microRNAs in Human Diseases: From Cancer to Inflammatory Disorder
Current Medicinal Chemistry Maintaining Plasma Fibrinogen Levels and Fibrinogen Replacement Therapies for Treatment of Intracranial Hemorrhage
Current Drug Targets Current Options in the Treatment of Mast Cell Mediator-Related Symptoms in Mastocytosis
Inflammation & Allergy - Drug Targets (Discontinued) COVID-19: Our Current Knowledge of Epidemiology, Pathology, Therapeutic Approaches, and Diagnostic Methods
Anti-Cancer Agents in Medicinal Chemistry Patent Selections
Recent Patents on Inflammation & Allergy Drug Discovery 5-HT1A Receptor, an Old Target for New Therapeutic Agents
Current Topics in Medicinal Chemistry Role of Hexokinase and VDAC in Neurological Disorders
Current Molecular Pharmacology Low-dose Tissue Plasminogen Activator is as Effective as Standard Tissue Plasminogen Activator Administration for the Treatment of Acute Ischemic Stroke
Current Neurovascular Research Early Ischemic Blood Brain Barrier Damage: A Potential Indicator for Hemorrhagic Transformation Following Tissue Plasminogen Activator (tPA) Thrombolysis?
Current Neurovascular Research Are the Extracelluar Pathways a Conduit for the Delivery of Therapeutics to the Brain?
Current Pharmaceutical Design Consequences of the α-Ketoglutarate Dehydrogenase Inhibition for Neuronal Metabolism and Survival: Implications for Neurodegenerative Diseases
Current Medicinal Chemistry The Critical Role of Vascular Endothelial Growth Factor in Tumor Angiogenesis
Current Cancer Drug Targets Hypoxic Preconditioning Increases Blood-Brain Barrier Disruption in the Early Stages of Cerebral Ischemia
Current Neurovascular Research COVID-19, the Brain, and the Future: Is Infection by the Novel Coronavirus a Harbinger of Neurodegeneration?
CNS & Neurological Disorders - Drug Targets Development of Liposomes and Pseudovirions with Fusion Activity for Efficient Gene Delivery
Current Gene Therapy Amine Oxidase Inhibitors and Development of Neuroprotective Drugs
Current Neuropharmacology Role of Graphene Nano-Composites in Cancer Therapy: Theranostic Applications, Metabolic Fate and Toxicity Issues
Current Drug Metabolism Stem Cell Therapy for Ischaemic Stroke: Translation from Preclinical Studies to Clinical Treatment
CNS & Neurological Disorders - Drug Targets Regulation of Cell Migration and Invasion by Specific Modules of uPA: Mechanistic Insights and Specific Inhibitors
Current Drug Targets Is Adult Hippocampal Neurogenesis Really Relevant for the Treatment of Psychiatric Disorders?
Current Neuropharmacology